Cancer Genetics Inc to Present New Data on Identification of Genomic Changes that Predict both Metastasis and Site of Metastasis in Kidney Cancer at the 2015 ASCO Genitourinary Cancers Symposium

By Italia on February 24 2015

CGI’s genomic signature, developed in a research collaboration with Memorial Sloan-Kettering, predicts metastasis for clear-cell renal cell carcinoma (ccRCC) Clear cell renal cell carcinoma is the most common form of kidney cancer with nearly 43,000 new cases in the US each year and 200,000 globally per year RUTHERFORD, NJ, February 24, 2015 (Globe Newswire) – […]

Continue Reading

Cancer Genetics’ Unique, Next Generation Sequencing Panel for Chronic Lymphocytic Leukemia (CLL) Selected for Use in Global Clinical Trial by Leading Biotechnology Company

By Italia on February 17 2015

CGI’s unique next generation sequencing (NGS) panel, Focus::CLLTM, will be used to assess genetic aberrations and mutations that are clinically relevant and validated for CLL, the most common form of leukemia in the Western hemisphere. CLL accounts for one-third of all leukemias and the Focus::CLLTM panel helps in determining patient outcome and treatment selection. RUTHERFORD, N.J. […]

Continue Reading

Cancer Genetics, Inc. to Participate in the BTIG Second Annual Snowbird Medical Technology, Diagnostics & Healthcare IT Conference

By Italia on February 12 2015

RUTHERFORD, N.J., Feb. 12, 2015 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “the Company”), an emerging leader in DNA-based cancer diagnostics, announced today that CEO and President Panna Sharma will participate in the BTIG Second Annual Snowbird Medical Technology, Diagnostics, and Healthcare IT Conference from February 18th to 20th. The conference, which is held at […]

Continue Reading

Cancer Genetics Appoints Randy Goodman, Ph.D., as Director of Reimbursement and Clinical Revenue Cycle Management

By Italia on February 11 2015

RUTHERFORD, NJ, February 11, 2015 (Globe Newswire) – Cancer Genetics, Inc. (Nasdaq: CGIX; “CGI” or “the Company”), an emerging leader in DNA-based cancer diagnostics, announced today the appointment of Randy Goodman, Ph.D., as Director of Reimbursement and Clinical Revenue Cycle Management. Goodman is a nationally recognized expert in value-based reimbursement and brings more than 20 […]

Continue Reading